ATP1A1-AS1: A Potential Drug Target and Biomarker for parkinson's disease

Target Name: ATP1A1-AS1

NCBI ID: G84852

ATP1A1-AS1

Other Name(s): ATP1A1-AS1 variant 4 | ATP1A1 antisense RNA 1, transcript variant 4 | ATP1A1OS | C1orf203 | ATP1A1 antisense RNA 1

ATP1A1-AS1: A Potential Drug Target and Biomarker for parkinson's disease

Parkinson's disease is a neurodegenerative disorder characterized by symptoms such as tremors, rigidity, and bradykinesia. It affects millions of people worldwide, primarily affecting older adults. The underlying cause of Parkinson's disease is the loss of dopamine-producing neurons in the brain, leading to a decline in neurotransmitter levels. While the exact cause of Parkinson's disease is still unknown, several studies have identified potential biomarkers and drug targets. In this article, we will focus on one such potential drug target, ATP1A1-AS1, and its implications as a diagnostic tool and potential therapeutic target for Parkinson's disease.

The Identification of ATP1A1-AS1

ATP1A1-AS1 is a gene that encodes for a protein known as the Atp1A1-AS1 transmembrane protein. This protein is expressed in the brain and has been implicated in the development and progression of Parkinson's disease. The Atp1A1-AS1 protein is composed of 12 transmembrane domains and contains several known protein domains, including an N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-spike domain.

The N-terminal transmembrane domain of Atp1A1-AS1 is rich in conserved electrolyte-binding sites, which suggests a potential role in intracellular signaling. The catalytic domain of Atp1A1-AS1 contains a catalytic cycle, which could be involved in the regulation of cellular processes such as metabolism and neurotransmitter signaling. The C-terminal T-spike domain is known for its role in intracellular signaling and is involved in the regulation of cellular processes such as cell survival and differentiation.

Several studies have suggested that Atp1A1-AS1 plays a role in the development and progression of Parkinson's disease. For example, studies have shown that Atp1A1-AS1 is overexpressed in the brains of individuals with Parkinson's disease and that overexpression of this gene has been associated with increased neurodegeneration in these individuals. Additionally, studies have shown that Atp1A1-AS1 is involved in the regulation of neurotransmitter synthesis and release, which may be involved in the pathophysiology of Parkinson's disease.

The Potential Implications of ATP1A1-AS1 as a Drug Target

The potential implications of ATP1A1-AS1 as a drug target are vast. If ATP1A1-AS1 is involved in the regulation of neurotransmitter synthesis and release, then targeting this gene could be a promising strategy for the development of new treatments for Parkinson's disease. Additionally, the N-terminal transmembrane domain of Atp1A1-AS1 is rich in conserved electrolyte-binding sites, which suggests that targeting this domain could be a promising strategy for the development of new treatments for other neurological disorders.

In conclusion, ATP1A1-AS1 is a gene that has significant implications for the development and progression of Parkinson's disease. The potential implications of ATP1A1-AS1 as a drug target are vast and continue to be the subject of ongoing research. Further studies are needed to fully understand the role of ATP1A1-AS1 in the pathophysiology of Parkinson's disease and to develop new treatments for this debilitating disorder.

Protein Name: ATP1A1 Antisense RNA 1

The "ATP1A1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP1A1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets